DK3288931T4 - Visse proteinkinaseinhibitorer - Google Patents

Visse proteinkinaseinhibitorer Download PDF

Info

Publication number
DK3288931T4
DK3288931T4 DK16785936.2T DK16785936T DK3288931T4 DK 3288931 T4 DK3288931 T4 DK 3288931T4 DK 16785936 T DK16785936 T DK 16785936T DK 3288931 T4 DK3288931 T4 DK 3288931T4
Authority
DK
Denmark
Prior art keywords
protein kinase
kinase inhibitors
certain protein
certain
inhibitors
Prior art date
Application number
DK16785936.2T
Other languages
English (en)
Other versions
DK3288931T3 (da
Inventor
Xingdong Zhao
Tongshuang Li
Haohan Tan
Zhifang Chen
Ling Chen
Qihong Liu
Yue Rong
Lijun Yang
Xianlong Wang
Rui Tan
Zuwen Zhou
Bin Liu
Min Lin
Lihua Jiang
Yanxin Liu
Li Linghu
Jing Sun
Weibo Wang
Original Assignee
Chongqing Fochon Pharmaceutical Co Ltd
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3288931(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chongqing Fochon Pharmaceutical Co Ltd, Shanghai Fochon Pharmaceutical Co Ltd filed Critical Chongqing Fochon Pharmaceutical Co Ltd
Publication of DK3288931T3 publication Critical patent/DK3288931T3/da
Application granted granted Critical
Publication of DK3288931T4 publication Critical patent/DK3288931T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK16785936.2T 2015-04-28 2016-04-28 Visse proteinkinaseinhibitorer DK3288931T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154082P 2015-04-28 2015-04-28
PCT/CN2016/080475 WO2016173505A1 (en) 2015-04-28 2016-04-28 Certain protein kinase inhibitor

Publications (2)

Publication Number Publication Date
DK3288931T3 DK3288931T3 (da) 2020-02-03
DK3288931T4 true DK3288931T4 (da) 2022-10-24

Family

ID=57198165

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16785936.2T DK3288931T4 (da) 2015-04-28 2016-04-28 Visse proteinkinaseinhibitorer

Country Status (10)

Country Link
US (1) US10450316B2 (da)
EP (1) EP3288931B2 (da)
CN (1) CN107849012B (da)
BR (1) BR112017023225A2 (da)
DK (1) DK3288931T4 (da)
ES (1) ES2766498T5 (da)
MX (1) MX395032B (da)
RU (1) RU2732952C2 (da)
TW (1) TWI696617B (da)
WO (1) WO2016173505A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778584A1 (en) 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2018113771A1 (en) 2016-12-22 2018-06-28 Betta Pharmaceuticals Co., Ltd Benzimidazole derivatives, preparation methods and uses theirof
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
CN111094291B (zh) 2017-08-11 2022-06-21 晟科药业(江苏)有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
TW201920141A (zh) * 2017-08-15 2019-06-01 中國大陸商北京軒義醫藥科技有限公司 Cdk4/6抑制劑及其用途
JP2021523208A (ja) 2018-05-14 2021-09-02 アリアド ファーマシューティカルズ, インコーポレイテッド ピリミジン誘導体の医薬塩及び障害の処置方法
CN113861191B (zh) 2018-06-21 2023-09-19 贝达药业股份有限公司 抑制cdk4/6活性化合物的晶型及其应用
CN116669741B (zh) * 2021-01-05 2025-07-22 山东轩竹医药科技有限公司 多环类激酶抑制剂
CN117222411B (zh) * 2021-03-24 2026-03-27 贝达药业股份有限公司 药物组合、包含其的试剂盒及其用途
WO2025016439A1 (zh) * 2023-07-19 2025-01-23 浙江同源康医药股份有限公司 用作cdk2/4蛋白激酶抑制剂的化合物及其应用
CN118405996B (zh) * 2024-04-23 2025-09-09 仁合益康集团有限公司 一种依伏卡塞的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005939A (es) * 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US8372851B2 (en) 2005-10-21 2013-02-12 Exelixis, Inc. Pyrazolo pyrimidines as casein kinase II (CK2) modulators
AU2007240496A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of CDC7
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
CA2753696A1 (en) * 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9796701B2 (en) * 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
CN104910137B (zh) 2014-03-10 2017-04-19 山东轩竹医药科技有限公司 Cdk激酶抑制剂
CA2954298A1 (en) 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
CN105153119B (zh) 2015-09-11 2019-01-01 广州必贝特医药技术有限公司 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用
CN106608879A (zh) * 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
RU2680777C1 (ru) * 2018-02-14 2019-02-26 Сергей Викторович Яблочко Направляющий аппарат центробежного многоступенчатого насоса

Also Published As

Publication number Publication date
TWI696617B (zh) 2020-06-21
RU2017141077A (ru) 2019-05-28
ES2766498T5 (es) 2022-11-18
EP3288931B2 (en) 2022-07-20
BR112017023225A2 (pt) 2018-08-07
MX395032B (es) 2025-03-24
EP3288931A1 (en) 2018-03-07
WO2016173505A1 (en) 2016-11-03
CN107849012B (zh) 2021-05-25
US10450316B2 (en) 2019-10-22
DK3288931T3 (da) 2020-02-03
RU2732952C2 (ru) 2020-09-24
TW201713645A (zh) 2017-04-16
CN107849012A (zh) 2018-03-27
ES2766498T3 (es) 2020-06-12
RU2017141077A3 (da) 2019-08-14
MX2017013875A (es) 2018-06-22
EP3288931A4 (en) 2018-10-10
EP3288931B1 (en) 2019-11-06
US20180291027A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
IL263586A (en) Inhibitors of the menin-mll interaction
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3365334T3 (da) Benzolactamforbindelser som proteinkinaseinhibitorer
IL254516A0 (en) Proteins specific for cd137
DK3442972T3 (da) Bromdomænehæmmere
LT3371171T (lt) Ret inhibitoriai
IL294381A (en) Pcna inhibitors
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
CL2016002502A1 (es) Inhibidores de biaril cinasa
EP3283077A4 (en) BROMDOMÄNENINHIBITOREN
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
MA42242A (fr) Inhibiteurs de la tyrosine kinase
DK3323269T3 (da) Målingsbaseret direkte adgangskonfiguration
DK3571192T3 (da) Jak1-selektive inhibitorer
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3288931T4 (da) Visse proteinkinaseinhibitorer
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3341379T3 (da) EZH2-hæmmere
LT3288944T (lt) Imidazopirazinonai, kaip pde1 inhibitoriai
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere